文献速递免疫规划传染病防控与疫情报告

奥密克戎感染后新冠后症状及加强接种效果:一项基于人群的队列研究

Post-COVID symptoms after SARS-CoV-2 omicron infection and the effect of booster vaccination: A population-based cohort study.
PubMed 文献 · Vaccine · 2025-01-08

该研究基于挪威四项问卷队列与全国健康登记数据,纳入超过31,000名未感染者和26,000名奥密克戎感染者,评估感染后3-5个月22种症状的超额风险。结果显示,近期接种加强针者感染后新发症状的超额风险低于仅接种两剂者,神经认知和心肺症状风险降低最明显。

要点

  • 感染前近期接种加强针者,感染后3-5个月新发症状超额风险女性为7%、男性最高5%。
  • 仅接种两剂者超额风险女性最高15%、男性最高9%,加强针降低风险。
  • 记忆差、脑雾和疲劳在近期加强接种后风险差异最大。

核心结论

  • 感染前近期接种加强针大幅降低了奥密克戎感染至少3个月后发生的神经认知和心肺症状。

研究设计与样本

  • 基于四项问卷队列与全国健康登记链接的基于人群的前瞻性研究。
  • 纳入挪威母亲、父亲和儿童队列、挪威流感妊娠队列、老年队列和青年成人队列中11-80岁女性与男性参与者。
  • 研究样本包括超过31,000名未感染者和26,000名奥密克戎感染者。
  • 感染者中12%在首次感染前超过130天(中位数154天)接种两剂但未接种第三剂,76%已接种第三剂(加强)剂(中位数感染前40天)。

主要发现

  • 仅接种两剂者感染后新发症状超额风险女性最高15%、男性最高9%。
  • 近期接种加强针的感染者对应超额风险女性为7%、男性最高5%。
  • 近期加强接种后风险差异最大的症状为记忆差、脑雾和疲劳。
  • 新冠后症状在青年和中年成人中比青少年和老年组更常检出。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of vaccination on the type and risk of specific post-COVID symptoms after Omicron infection is not clear. We aimed to investigate the excess risk and patterns of 22 symptoms 3-5 months after Omicron infection, comparing uninfected and infected subjects with and without recent booster vaccination. METHODS: We conducted a population-based prospective study based on four questionnaire-based cohorts linked to national health registries. Our study includes female and male participants aged 11-80 years from The Norwegian Mother, Father, and Child Cohort Study, The Norwegian Influenza Pregnancy Cohort, The Senior Cohort, and The Young Adult Cohort. All participants registered presence of 22 COVID-related symptoms irrespective of infection and vaccination status. RESULTS: The study sample includes more than 31,000 uninfected and 26,000 Omicron infected subjects. Among infected subjects, 12 % were vaccinated with two doses >130 days before the primary infection (median 154 days) but had not received a third dose, while 76 % had received a third (booster) dose (median 40 days before infection). Among those with two doses only, the excess risk for new symptoms after infection (vs. no infection) were up to 15 % for women and 9 % for men. Among infected subjects with recent booster dose, the corresponding excess risks were 7 % among women and up to 5 % among men. The largest risk differences after recent booster vaccination were seen for poor memory, brain fog, and fatigue. Post-COVID symptoms were more often detected among young and middle-aged adults than among adolescents and older age groups. CONCLUSION: Recent booster vaccination before infection substantially reduced both neurocognitive and cardiorespiratory symptoms occurring at least 3 months after Omicron infection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Caspersen IH, Skodvin SN, Blix K, et al. Post-COVID symptoms after SARS-CoV-2 omicron infection and the effect of booster vaccination: A population-based cohort study. Vaccine. 2025. PMID: 39787799. doi:10.1016/j.vaccine.2024.126664

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。